Swine flu jabs to be
repackaged as seasonal flu jabs, reports FT
June 30, 2010 by Jane
Swine flu pandemic vaccines are to be given to
people as seasonal flu jabs in Europe and the
USA from autumn, according to a report in the
The FT's Andrew Jack says that the gigantic
surplus stocks of inadequately tested swine flu
jabs with adjuvants are to be incorporated into
the upcoming seasonal flu jab.
Governments are sitting on millions of jabs
after they were rejected by tens of millions of
people in Europe and the USA over safety
„If the drug companies see disappointing sales
ahead, they have one compensation: modest cost
savings through the use of surplus bulk stocks
of H1N1 antigen prepared for the pandemic
vaccine they can divert into their seasonal flu
products," Jack writes on June 28th.
In a report on the swine flu vaccination
campaign for the Council of Europe, UK MP Paul
Flynn last week concluded that billions of
pounds of tay payer's money was wasted around
the world on buying vaccines and drugs to fight
a swine flu "pandemic that never was".
"They [WHO] frightened the whole world with the
possibility that a major plague was on the way,"
"The result of that was that the world spent
billions and billions of pounds on vaccines and
anti-virals that will never be used. It is huge
waste of money."
A review of the mass swine flu campaign is also
being conducted by the French parliament.
But it seems the swine flu jabs have not gone
The WHO says the H1N1 pandemic swine flu virus
has displaced other seasonal flu viruses, and
has recommended it should be one of three
strains in the vaccine for the coming winter flu
season in Europe and the USA and Asia.
The vaccine is already being used in Australia
and has sparked significant safety fears.
Australia's Chief Medical Officer, Professor Jim
Bishop, called on June 11th for doctors to stop
giving the new seasonal flu vaccine to children
five years and under because so many had to be
hospitalised following the jab. There were even
deaths reported in Western Australia.
The FT's Andrew Jack notes growing awareness of
the lack of safety data on the swine flu jab and
the lax controls when it comes to
pharmacovigilance has made people more reluctant
to take flu jabs, hurting the profits of
"European scepticism towards flu vaccines has
left drug companies braced for flat sales across
the EU this winter, in spite of the heightened
profile and continued threat of infection caused
by the pandemic over the past year," he writes.
"Sanofi-Aventis, GlaxoSmithKline and Novartis,
the world's largest vaccine makers, are all
predicting no rise in demand across the EU,
while expecting greater uptake in the US,
bringing their estimated collective annual sales
of flu vaccines over this year and last to more
A panel advising the CDC has recommended almost
all Americans be obliged to new flu jab this
autumn, but Jack indicates that Europeans could
also soon face pressure to take the new jab.
"[A lower uptake in Europe] will spark fresh
debate over whether the EU needs to strengthen
measures to protect its citizens against flu,"
"Andrin Oswald, head of vaccines at Novartis,
said: "I'm a bit concerned that there is
scepticism towards flu vaccines in some
countries in Europe," writes Jack.